Physician profile
Gregory T Davis
NPI 1962599860
$1,035.42
in general payments reported to CMS, 2019-2025
19 companies · $180 in 2025
The $180 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32.25 · 2020: $28.65 · 2021: $102 · 2022: $175 · 2023: $317 · 2024: $200 · 2025: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $697.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $697.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $251.38 | 2021-2023 | Puraply |
| Paratek Pharmaceuticals, INC. | $219.34 | 2021-2025 | Nuzyra |
| Averitas Pharma INC. | $109.24 | 2023-2025 | Qutenza |
| Nabriva Therapeutics, Plc | $66.41 | 2022 | |
| Amgen INC. | $54.43 | 2024 | Krystexxa |
| Kerecis Limited | $46.10 | 2022-2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Abbott Laboratories | $39.43 | 2023-2024 | Proclaim |
| Globus Medical, INC. | $32.25 | 2025 | Senza |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $28.79 | 2021-2023 | Jublia |
| Fidia Pharma USA INC. | $28.65 | 2020 | |
| Ani Pharmaceuticals, INC. | $22.64 | 2025 | Purified Cortrophin Gel |
| Treace Medical Concepts, INC. | $21.46 | 2025 | |
| Zimvie INC. | $20.88 | 2022 | |
| Bioventus LLC | $20.87 | 2024 | Exogen Ultrasound Bone Healing System |
| Horizon Therapeutics Plc | $16.88 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $15.64 | 2024 | |
| Boston Scientific Corporation | $15.37 | 2019 | |
| Sebela Pharmaceuticals INC. | $13.19 | 2022 | |
| Hikma Pharmaceuticals USA | $12.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.